Company Profile

Tansna Therapeutics Inc
Profile last edited on: 9/8/2014      CAGE: 65SY8      UEI: PLK6CFD4TF25

Business Identifier: Oral Medication to treat Epilepsy
Year Founded
2010
First Award
2011
Latest Award
2011
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

4320 Forest Park Avenue Suite 303
St Louis, MO 63108
   (860) 938-2315
   N/A
   www.tansna.com
Location: Single
Congr. District: 01
County: St. Louis city

Public Profile

Tansna Therapeutics, Inc., is a drug discovery and development company focused on novel therapies for the treatment of CNS disorders, with an initial focus on epilepsy. The company has identified a library of proprietary compounds that are derivatives of the marketed anesthetic propofol. These compounds are drug-like small-molecules, exhibit broad-spectrum CNS pharmacology, and are non-sedating. Tansna’s lead is a novel anticonvulsant for the treatment of epilepsy - a debilitating condition and one of the most common neurological disorders with at least 50 million people affected worldwide. Chronic, daily treatment with anticonvulsant drugs continues to be the standard of care for these patients, who often require several drugs and endure severe side effects (including headache, fatigue, and cognitive impairment) in an attempt to manage their seizures. Despite these efforts, a staggering 30% of epilepsy patients are refractory, which means that they are unable to achieve adequate seizure control using existing medications. Thus, there remains a significant unmet need for more effective and safer anticonvulsant drugs. Tansna aims to develop an oral anticonvulsant agent with an acceptable safety profile that will effectively reduce seizure frequency in all epilepsy patients, particularly those with refractory epilepsy. Previously located in Iowa, in 2013 Tansna relocated to St Louis due to the avaliablity investment funding from Missouri based organizations.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2011 1 NIH $181,299
Project Title: Design and Synthesis of Novel Anticonvulsant Molecules.

Key People / Management

  Robert Karr -- President and Chief Executive Officer

  Kathleen Larrimer Beckmann -- Chief Financial Officer:

  George H Capps -- Director Of Business Development

  Alan Macinnes -- Vice President, Research And Development

  Rajesh Kumar Mishra